TG Therapeutics is a biopharmaceutical company focused on B-cell malignancies & autoimmune disease. Ublituximab is a novel, glycoengineered mAb that targets a unique epitope on the CD20 antigen. Umbralisib is an oral PI3K delta inhibitor with a differentiated safety profile. Ph 3 - GENUINE for R/R high-risk CLL patients (IB vs. IB + ublituximab) ASCO17 (Sharman et al). UNITY Trials combine umbralisib & ublituximab (U2 regimen). UNITY-CLL studied >600 frontline & R/R CLL pts (Topline data 2Q18). UNITY-NHL is for R/R DLBCL, FL/SLL. MZL, MCL. Preclinical compounds include BTK, BET, PDL-1, GITR.